Drugs / NOVOCART® 3D plus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01656902 | May 2013 → Mar 2020 | arthropathy | Tetec AG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NOVOCART 3D plus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01656902 ↗ |
| Modality | Cell therapy | “collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location” NCT01656902 ↗ |
| Route | Other | “implanted into the defect location (knee, femur)” NCT01656902 ↗ |